IMMX (Immix Biopharma) ROC (Joel Greenblatt) %: -1,509.36% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMX Immix Biopharma Inc IMMX
22 GF Score
Price $13.67
! 2 Warning Signs
View Full Analysis

What is Immix Biopharma ROC (Joel Greenblatt) %?

Immix Biopharma IMMX +3.80% 22 ROC (Joel Greenblatt) % is -1,509.36% as of Jun. 2026. GuruFocus rates IMMX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,325 Biotechnology companies, Immix Biopharma ranks worse than 69.81% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Immix Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -1,509.36%.

The historical rank and industry rank for Immix Biopharma's ROC (Joel Greenblatt) % or its related term are showing as below:

IMMX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -59781.48   Med: -8420   Max: -963.37
Current: -1256.94

During the past 7 years, Immix Biopharma's highest ROC (Joel Greenblatt) % was -963.37%. The lowest was -59781.48%. And the median was -8420.00%.

IMMX's ROC (Joel Greenblatt) % is ranked worse than
69.81% of 1325 companies
in the Biotechnology industry
Industry Median: -301.94 vs IMMX: -1256.94

Immix Biopharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 37.10% per year.


Immix Biopharma  (NAS:IMMX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Immix Biopharma ROC (Joel Greenblatt) % Related Terms


Immix Biopharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Immix Biopharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immix Biopharma ROC (Joel Greenblatt) % Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -12,837.14 -4,395.19 -59,781.48 -1,631.29 -963.37

Immix Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -857.02 -936.94 -1,271.62 -1,262.70 -1,509.36

IMMX vs CBIO, NVCT, ALLO: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Immix Biopharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immix Biopharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's ROC (Joel Greenblatt) % falls into.


IMMX
22GF Score
Immix Biopharma Inc IMMX
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immix Biopharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.696) - (9.534 + 0 + 0.881)
=-8.719

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.683) - (9.017 + 0 + 0.174)
=-7.508

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Immix Biopharma for the quarter that ended in Jun. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-49.824/( ( (3.356 + max(-8.719, 0)) + (3.246 + max(-7.508, 0)) )/ 2 )
=-49.824/( ( 3.356 + 3.246 )/ 2 )
=-49.824/3.301
=-1,509.36 %

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1,509.36% mean?
Immix Biopharma (IMMX) has a ROC (Joel Greenblatt) % of -1,509.36% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Immix Biopharma and its competitors. According to the industry distribution chart, Immix Biopharma ranks #925 out of 1325 companies in the Biotechnology industry, placing it in the top 69.8%.
Is Immix Biopharma's ROC (Joel Greenblatt) % too high?
Immix Biopharma's current ROC (Joel Greenblatt) % is -1,509.36%. Based on the distribution chart, Immix Biopharma ranks #925 out of 1325 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immix Biopharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Immix Biopharma's ROC (Joel Greenblatt) % compare to CBIO and NVCT?
According to the Biotechnology industry distribution chart, Immix Biopharma ranks #925 out of 1325 companies for ROC (Joel Greenblatt) %. This places Immix Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Immix Biopharma and its competitors. Immix Biopharma's current ROC (Joel Greenblatt) % is -1,509.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immix Biopharma stock overvalued right now?
Immix Biopharma (IMMX) has a current ROC (Joel Greenblatt) % of -1,509.36%. The current ROC (Joel Greenblatt) % is -1,509.36%. Immix Biopharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Immix Biopharma (IMMX), the current ROC (Joel Greenblatt) % is -1,509.36% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immix Biopharma Business Description

Address 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
22GF Score

Get the complete analysis for IMMX

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.67
Price